Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two departures shake up AZ's immuno-oncology leadership

This article was originally published in Scrip

Executive Summary

Two of AstraZeneca's immuno-oncology leaders have left the company simultaneously, though AstraZeneca has said that the timing of the departures is coincidental. Rachel Humphrey, formerly senior vice-president and head of immune-oncology, left at the end of November for personal reasons. She has been replaced by Robert Iannone, who has worked for AZ since last year as part of the global medicines team. Mr Iannone was previously executive director of clinical research, and section head in oncology at Merck Research Laboratories.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts